obesity and glp 1 Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Medicine Association, The Obesity Society - The GLP-1 Access Gap: Mapping

Moxit Shah, DM EndocrinologyConsultant Endocrinologist | Ahmedabad Appointment: 9979992797 Introduction For years, people struggling with obesity were told to "eat less and exercise more." While healthy lifestyle changes remain the foundation of weight management, modern science has shown that obesity is a chronic hormonal disease, not simply a lack of willpower

Exaggerated GLP-1 secretion underlies hyperinsulinemic #hypoglycemia in some individuals post #bariatric surgery and contributes to improved beta cell function

While weight loss effects can vary depending on the drug, studies show that all GLP-1 meds can result in an average weight loss of about 10.5 to 15.8 []

To conclude, the food intake reducing effects of exenatide may temporally evolve from strong anorectic to weak anhedonic modulations, where hedonic experience and anticipation during the early anorectic phase is conserved but uncoupled from food intake behaviour.

Energy fluctuations linked to unstable blood sugar patterns

However, medication alone is rarely the complete answer